Zeitschrift für Gastroenterologie, Table of Contents Z Gastroenterol 2016; 54(10): 1170-1171DOI: 10.1055/s-0042-113195 Kommentar © Georg Thieme Verlag KG Stuttgart · New YorkOptionen zur optimierten Therapie der Helicobacter-pylori-InfektionOptions for the optimized therapy of Helicobacter pylori infectionAuthors Author Affiliations C. Lübbert 1 Fachbereich Infektions- und Tropenmedizin, Klinik für Gastroenterologie und Rheumatologie, Universitätsklinikum Leipzig, Germany 2 Interdisziplinäres Zentrum für Infektionsmedizin, Universitätsklinikum Leipzig, Germany R. Vogelmann 3 II. Medizinische Klinik, Universitätsklinikum Mannheim, Germany B. Salzberger 4 Stabstelle Infektiologie, Universitätsklinikum Regensburg, Germany W. V. Kern 5 Abteilung Infektiologie, Klinik für Innere Medizin II, Universitätsklinikum Freiburg, Germany Recommend Article Abstract Buy Article(opens in new window)Schlüsselwörter SchlüsselwörterHelicobacter pylori - Antibiotika - ABS - Leitlinie Key words Key wordsHelicobacter pylori - antibiotics - antimicrobial stewardship - guideline Full Text References Literatur 1 McNulty CA, Dent JC. Susceptibility of clinical isolates of Campylobacter pylori to twenty-one antimicrobial agents. Eur J Clin Microbiol Infect Dis 1988; 7: 566-569 2 Borody TJ, Cole P, Noonan S et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust 1989; 151: 431-435 3 Fischbach W, Malfertheiner P, Lynen Jansen P et al. S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit. Z Gastroenterol 2016; 54: 327-363 4 de With K, Allerberger F, Amman S et al. Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases. Infection 2016; 44: 395-439 5 Odenholt I, Cars O, Löwdin E. Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens. J Antimicrob Chemother 2004; 54: 1062-1066 6 Ewig S, Höffken G, Kern WV et al. S3-Leitlinie Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und Prävention – Update 2016. http://www.awmf.org/uploads/tx_szleitlinien/020-020l_S3_ambulant_erworbene_Pneumonie_Behandlung_Praevention_2016-02-2.pdf 7 Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333: 984-991 8 Ren L, Lu H, Li HY et al. New dual therapy for primary treatment of Helicobacter pylori infection: A prospective randomized study in Shanghai, China. J Dig Dis 2014; 15: 622-627 9 Yang JC, Lin CJ, Wang HL et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2015; 13: 895-905.e5 10 Bayerdörffer E, Miehlke S, Mannes GA et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995; 108: 1412-1417 11 Delchier JC, Elamine I, Goldfain D et al. Omeprazole-amoxicillin versus omeprazole-amoxicillin-clarithromycin in the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996; 10: 263-268 12 Fachinformation Moxifloxacin – 400 mg Filmtabletten.
